LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

LSKL，血小板反应蛋白 (TSP-1) 抑制剂 (TFA)

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)

L661589-1ml

1ml

10mM in DMSO

干燥,-80℃储存

超低温冰袋运输

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal inte IC50& Target:TGF-β1 In Vitro:The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombo In Vivo:LSKL, Inhibitor of Thrombospondin (TSP-1) (1mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin ( Biological Activity:LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal inte

C23H43F3N6O7

572.62 g/mol